Business
Interim Results
Cardiogeni plc reported zero turnover for the six months ending September 30, 2025, compared to £7,750,787 in the prior full year, resulting in a loss of £532,914 versus a profit of £1,022,997. The company's cash and cash equivalents increased to £382,124. Key developments include the incorporation of Cardiogeni Limited in the UAE as a joint venture with expected non-dilutive license funding of $25 million (~£19 million) and a £650,000 private placement. The company is preparing for Phase IIb/3 studies in the GCC region in Q1 2026, with a significant risk identified as the completion of the UAE JV funding agreement. Disclaimer*
About this update from Cardiogeni Plc
[{"type":"text","content":"\n\n29th December 2025\n \nCardiogeni plc\n(\"Cardiogeni\" or the \"Company\")\n \nInterim Results - Period April 1st 2025 to 30th September 2025\nCardiogeni plc (AQSE: CGNI), the listed biotech company focused on developing first in class cell therapy medicines to treat heart failure, announces its unaudited interim financial results for the six-month period ended 30 September 2025, which include the previously reported audited results for the twelve-month period ended 31 March 2025.\nCopies of the Chairman and Financial Statements will be made available in the announcements section of the Company's website (cardiogeni.com).\nInterim management report \nThe company has made significant progress versus its strategic plan in the period to 30th September 2025 and the post period leading up to the publication of these interim results.\nHighlights\n· Turnover in the period was Zero (Full Year to 31st March 2025: £7,750,787) and the loss was £532,914 (Full Year to 31st March 2025: £1,022,997 profit)*\n· Cash and cash equivalents at end of period was £382,124 (Full Year to 31st March 2025 £359,759).\n· Incorporated Cardiogeni Limited in the United Arab Emirates (UAE) as a joint venture (JV) with investment partners to undertake the clinical development and commercialisation of Cardiogeni's novel heart failure medicines in UAE and Gulf Cooperation Council region (\"GCC\").\n· The principal terms of the JV include $25M (~£19M) in non-dilutive license funding expected to be received in tranches in 2026 and 2027.\n· Raised £650,000 via a private placement of 3,757,227 shares at 17.3p.\n· Appointed SP Angel Corporate Finance LLP as the Company's Corporate Broker.\n· Announced a contingent EIS funding round including advanced subscription agreements of £150,000\n· Appointed Lord James Bethell as Non-Executive Director\n \n* The full year turnover to March 31st, 2025, of £7,794.587 (2024:667,027) and profit of £1,095,796 (2024 loss: £280,606) were primarily driven by the recognition of the remaining accrued revenue from the historical collaboration and license agreement with D...